Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL CONGESTION RELIEF vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
92-98% bound primarily to albumin.
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
Safety and efficacy not established; use is not recommended in pediatric patients.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
No FDA black box warning.
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL CONGESTION RELIEF vs ADALAT CC, answered by our medical review team.
ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL CONGESTION RELIEF and ADALAT CC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL CONGESTION RELIEF and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.